SEC Form 4 · accession 0001387131-15-000229
Adamis Pharmaceuticals Corp · ADMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Moll
Officer — VP of Research
Period of report
Jan 23, 2015
Accepted (ET)
Jan 27, 2015 · 5:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000887247
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $5.99 | Jan 23, 2015 | A | 65,050 | A | — | Jan 23, 2025 | common stock | 65,050 | 65,050 | D |
Explanation of responses
- F1The option vests and becomes exercisable as to 1/36 of the option shares on each monthly anniversary of the grant date.